160 related articles for article (PubMed ID: 37291647)
1. Reasonable access: important characteristics and perceived quality of legal and illegal sources of cannabis for medical purposes in Canada.
Capler NR; Balneaves LG; Buxton JA; Kerr T
J Cannabis Res; 2023 Jun; 5(1):18. PubMed ID: 37291647
[TBL] [Abstract][Full Text] [Related]
2. Are dispensaries indispensable? Patient experiences of access to cannabis from medical cannabis dispensaries in Canada.
Capler R; Walsh Z; Crosby K; Belle-Isle L; Holtzman S; Lucas P; Callaway R
Int J Drug Policy; 2017 Sep; 47():1-8. PubMed ID: 28667878
[TBL] [Abstract][Full Text] [Related]
3. Reasons for Purchasing Cannabis From Illegal Sources in Legal Markets: Findings Among Cannabis Consumers in Canada and U.S. States, 2019-2020.
Goodman S; Wadsworth E; Hammond D
J Stud Alcohol Drugs; 2022 May; 83(3):392-401. PubMed ID: 35590180
[TBL] [Abstract][Full Text] [Related]
4. Noticing of cannabis health warning labels in Canada and the US.
Goodman S; Hammond D
Health Promot Chronic Dis Prev Can; 2021; 41(7-8):201-210. PubMed ID: 34427418
[TBL] [Abstract][Full Text] [Related]
5. The impact of legalization of access to recreational Cannabis on Canadian medical users with Cancer.
Hawley P; Gobbo M; Afghari N
BMC Health Serv Res; 2020 Oct; 20(1):977. PubMed ID: 33109169
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis markets.
Goodman S; Wadsworth E; Leos-Toro C; Hammond D;
Int J Drug Policy; 2020 Feb; 76():102658. PubMed ID: 31927413
[TBL] [Abstract][Full Text] [Related]
7. Barriers to access for Canadians who use cannabis for therapeutic purposes.
Belle-Isle L; Walsh Z; Callaway R; Lucas P; Capler R; Kay R; Holtzman S
Int J Drug Policy; 2014 Jul; 25(4):691-9. PubMed ID: 24947993
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada.
Leung J; Chan G; Stjepanović D; Chung JYC; Hall W; Hammond D
Psychopharmacology (Berl); 2022 May; 239(5):1509-1519. PubMed ID: 35020045
[TBL] [Abstract][Full Text] [Related]
9. Availability, retail price and potency of legal and illegal cannabis in Canada after recreational cannabis legalisation.
Mahamad S; Wadsworth E; Rynard V; Goodman S; Hammond D
Drug Alcohol Rev; 2020 May; 39(4):337-346. PubMed ID: 32291811
[TBL] [Abstract][Full Text] [Related]
10. Consumer perceptions of legal cannabis products in Canada, 2019-2021: a repeat cross-sectional study.
Wadsworth E; Fataar F; Goodman S; Smith DM; Renard J; Gabrys R; Jesseman R; Hammond D
BMC Public Health; 2022 Nov; 22(1):2048. PubMed ID: 36348479
[TBL] [Abstract][Full Text] [Related]
11. Cannabis advertising, promotion and branding: Differences in consumer exposure between 'legal' and 'illegal' markets in Canada and the US.
Rup J; Goodman S; Hammond D
Prev Med; 2020 Feb; 133():106013. PubMed ID: 32027914
[TBL] [Abstract][Full Text] [Related]
12. Price elasticity of illegal versus legal cannabis: a behavioral economic substitutability analysis.
Amlung M; Reed DD; Morris V; Aston ER; Metrik J; MacKillop J
Addiction; 2019 Jan; 114(1):112-118. PubMed ID: 30194789
[TBL] [Abstract][Full Text] [Related]
13. Cannabis flower prices and transitions to legal sources after legalization in Canada, 2019-2020.
Wadsworth E; Driezen P; Pacula RL; Hammond D
Drug Alcohol Depend; 2022 Feb; 231():109262. PubMed ID: 34998249
[TBL] [Abstract][Full Text] [Related]
14. Trends in the use of cannabis products in Canada and the USA, 2018 - 2020: Findings from the International Cannabis Policy Study.
Hammond D; Goodman S; Wadsworth E; Freeman TP; Kilmer B; Schauer G; Pacula RL; Hall W
Int J Drug Policy; 2022 Jul; 105():103716. PubMed ID: 35613480
[TBL] [Abstract][Full Text] [Related]
15. Behavioral economic analysis of legal and illegal cannabis demand in Spanish young adults with hazardous and non-hazardous cannabis use.
González-Roz A; Belisario K; Secades-Villa R; Muñiz J; MacKillop J
Addict Behav; 2024 Feb; 149():107878. PubMed ID: 37924581
[TBL] [Abstract][Full Text] [Related]
16. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients.
Lucas P; Walsh Z
Int J Drug Policy; 2017 Apr; 42():30-35. PubMed ID: 28189912
[TBL] [Abstract][Full Text] [Related]
17. Co-use of cannabis and alcohol before and after Canada legalized nonmedical cannabis: A repeat cross-sectional study.
Hobin E; Weerasinghe A; Boniface S; Englund A; Wadsworth E; Hammond D
J Psychopharmacol; 2023 May; 37(5):462-471. PubMed ID: 37039435
[TBL] [Abstract][Full Text] [Related]
18. Legal sourcing of ten cannabis products in the Canadian cannabis market, 2019-2021: a repeat cross-sectional study.
Wadsworth E; Rynard V; Driezen P; Freeman TP; Rychert M; Wilkins C; Hall W; Gabrys R; Hammond D
Harm Reduct J; 2023 Feb; 20(1):19. PubMed ID: 36803833
[TBL] [Abstract][Full Text] [Related]
19. Do Mandatory Health Warning Labels on Consumer Products Increase Recall of the Health Risks of Cannabis?
Goodman S; Leos-Toro C; Hammond D
Subst Use Misuse; 2022; 57(4):569-580. PubMed ID: 34989662
[TBL] [Abstract][Full Text] [Related]
20. Consumer perceptions of 'legal' and 'illegal' cannabis in US states with legal cannabis sales.
Fataar F; Goodman S; Wadsworth E; Hammond D
Addict Behav; 2021 Jan; 112():106563. PubMed ID: 32768793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
